NCT01004991 - Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

September 30, 2013

Study Completion Date

February 29, 2016

Conditions

Diffuse Large B Cell Lymphoma

Interventions

BIOLOGICAL

rituximab

375 mg/m2 on Day 8 of each of 6 cycles

DRUG

cyclophosphamide

750 mg/m2 on Day 8 of each of 6 cycles

DRUG

vincristine

1.4 mg/m2 on Day 8 of each of 6 cycles

DRUG

doxorubicin

50 mg/m2 on Day 8 of each of 6 cycles

DRUG

prednisone

100 mg PO days 8-12 of each of 6 cycles

DRUG

azacytidine

Dose level 1: azacytidine 25 mg/m2 days 1-5 Dose level 2: azacytidine 50 mg/m2 days 1-5 Dose level 3: azacytidine 75 mg/m2 days 1-5

Trial Locations (1)

Weill Cornell Medical College, New York